

**Comparative study between thrombolytic therapy and  
surgery in 30 cases of acute left sided prosthetic valve  
thrombosis**

*Thesis*

**Submitted for fulfillment of the requirement of Master Degree  
in  
Critical Care Medicine**

**Investigator**

**Mohamed Fawzi Abdu Abdu**

*MB.B.CH*

**Supervisors**

**Prof. Dr. Ayman El Naggar**

Professor of Critical Care Medicine

Critical Care Department

Cairo University

**Dr. Mohamed Fawzi**

Lecturer of Critical Care Medicine,

Critical Care Department,

Cairo University

**Dr. Gada Kazamel**

Consultant of Cardiovascular

Medicine,

National Heart Institute,

*Cairo University*

2013

# *Acknowledgement*

First of all I would like to thank **GOD** for his mercy and gifts, and for helping me to achieve this study.

All thanks to *Professor Dr. Sherif Mokhtar*, professor of critical care medicine, faculty of medicine, Cairo University for giving us the opportunity to perform such work by the construction of the most successful department at el kasr el ainy hospital.

Many thanks to *Professor Dr. Ayman El-naggar*, professor of critical care medicine and *Dr Mohammad Fawzy Abdelaleem* lecturer of critical care medicine, faculty of medicine, Cairo University and *Dr Ghada Kazamel* consultant of cardiology in NHI for their great encouragement, valuable directions and outstanding help and for their sincere supervision throughout the work of this thesis.

Mohammad Fawzy Abdu  
2013

## **Abstract**

**The study included 30 patients that were divided into two groups each of them included 15 patients. Group A received thrombolytic therapy while group B had done redo surgery. The mortality was 4 patients in thrombolytic group as compared to 2 mortality cases in the surgical group. The partial success was 2 cases in thrombolytic group. As regard the 2 pregnant in thrombolytic group they had a viable fetus as compared to 2 cases of IUFD in surgical group.**

**Key words: comparative study , acute left-sided prosthetic valve thrombosis , surgical redo, thrombolytic therapy**

# ***Contents***

<b>Introduction</b> .....	<b>1</b>
<b>Aim of The Work</b> .....	<b>5</b>
<b>Review of Literature</b> .....	<b>6</b>
<b>Patients &amp; Methods</b> .....	<b>93</b>
<b>Results</b> .....	<b>101</b>
<b>Discussion</b> .....	<b>131</b>
<b>Summary</b> .....	<b>191</b>
<b>Conclusions</b> .....	<b>198</b>
<b>Recommendation</b> .....	<b>206</b>
<b>References</b> .....	<b>208</b>
<b>Arabic Summary</b> .....	<b>٥-١</b>

## **List of abbreviations**

AATS	:	American Association for Thoracic Surgery
ABG	:	Arterial blood gas
ACC	:	American College of Cardiology
ACCP	:	American College of Chest Physicians
AF	:	Atrial fibrillation.
AHA	:	American Heart Association
APSAC	:	Anisoylated Plasminogen streptokinase activator
aPTT	:	Activated partial thromboplastin time
ATS	:	Advancing the Standard
AVN	:	Atrio ventricular node
CA	:	Closing angel
Cath lab	:	Catheterization laboratory.
CC	:	Closing Click.
CHB	:	Complete heart block.
CPAP	:	Continuous positive airway pressure
CPB	:	Cardio pulmonary bypass
CPR	:	Cardio pulmonary recussitation
CVA	:	Cerebro Vascular Accident.
CVC	:	Central venous catheter
Diag.	:	Diagonal artery
DM	:	Diastolic murmur
DVT	:	Deep vein thrombosis
ER	:	Emergency room
FDA	:	Food and Drug Administration
GIT	:	Gastro intestinal tract.
GFR	:	Glomerular filtration rate

h	:	hour
IMV	:	Invasive mechanical ventilation.
I.V	:	Intra venous
ICU	:	Intensive care unit
INR	:	International normalized ratio
K	:	potassium
LAA	:	Left atrial appendage
LA	:	Left atrium
LAD	:	Left anterior descending artery.
LL	:	Lower limb
LMWH	:	Low Molecular Weight Heparin
LV	:	Left ventricle
MC	:	Mitral closing sound
MRSA	:	Methicillin resistant staph aureus.
MSSA	:	Methicillin sensitive staph aureus
MVA	:	Mitral Valve Area
NHI	:	National Heart Institute.
NIMV	:	None invasive mechanical ventilation.
NYHA	:	New York Heart Association
OA	:	Open angel
OC	:	Opening Click
P2	:	Pulmonic component of the second heart sound
PS	:	Pressure support
PVT	:	Prosthetic Valve Thrombosis
PMVT	:	Prosthetic Mitral Valve Thrombosis
RAAS	:	Rennin angiotensin aldosterone system
RBF	:	Renal blood flow
RRT	:	Renal replacement therapy.
RSI	:	Rapid sequence induction

rt- PA	:	Recombinant tissue plasminogen activator
RV	:	Right ventricle.
S1	:	First heart sound.
S2	:	Second heart sound.
SC	:	Subcutaneous.
SD	:	Standard of deviation.
SEM	:	Systolic ejection murmur
SK	:	Streptokinase.
SLE	:	Systemic lupus erythromatosis
SR	:	Sinus rhythm
STEMI	:	ST segment elevation myocardial infarction.
St.Jude	:	Saint Jude (trade mark)
STS	:	Society of Thoracic Surgeon
TEC	:	Thrombo Embolic Complication.
TEE	:	Trans Esophageal Echocardiography
TIA	:	Transient ischaemic attack
TTE	:	Trans Thoracic Echocardiography
UFH	:	Unfractionated heparin
UK	:	urokinase
u- PA	:	Urokinase type- Plasminogen Activator
u	:	unit
VF	:	Ventricular fibrillation
VVI	:	Single chamber pacemaker pacing and sensing the ventricle.
WHO	:	World Health Organization.

## ***List of Figures***

<b>Item</b>		<b>Page</b>
<b><i>Figure (1):</i></b>	Flow patterns of mechanical valves	14
<b><i>Figure (2):</i></b>	Profiles of mechanical mitral valve prostheses	14
<b><i>Figure (3):</i></b>	A) Bileaflet valve in opening position B) Bileaflet valve in closing position.	23
<b><i>Figure (4):</i></b>	The relation between the dimensions of the thrombus and the rate of complications	81
<b><i>Figure (5):</i></b>	Flow chart showing the broad lines of our study	99
<b><i>Figure (6):</i></b>	The aPTT between the two groups	102
<b><i>Figure (7):</i></b>	The INR between the two groups	102
<b><i>Figure (8):</i></b>	Showing the coagulation profile history between the two groups	103
<b><i>Figure (9):</i></b>	Showing the redo surgeries previously done	105
<b><i>Figure (10):</i></b>	Showing the past history of thrombosis between the two groups	107
<b><i>Figure (11):</i></b>	Showing the difference in hemodynamics in the whole patients before and after treatment.	113
<b><i>Figure (12):</i></b>	Showing the respiratory improvement after thrombolytic therapy	115
<b><i>Figure (13):</i></b>	Showing the difference in renal functions between the two groups	122
<b><i>Figure (14):</i></b>	Showing the need for RRT in the two groups.	122
<b><i>Figure (15):</i></b>	Showing the pregnancy outcome in the two groups.	123
<b><i>Figure (16):</i></b>	Showing the reduction in peak gradient after thrombolytic therapy.	127



<b>Item</b>		<b>Page</b>
<b>Figure (17):</b>	Showing the reduction in mean gradient after thrombolytic therapy.	127
<b>Figure (18):</b>	Showing the reduction in PASP after thrombolytic therapy.	128
<b>Figure (19):</b>	Showing the increase in valve area after thrombolytic therapy.	128
<b>Figure (20):</b>	Showing the reduction of thrombus size measured by TEE after thrombolytic therapy.	129
<b>Figure (21):</b>	Showing the different patterns of acute renal failure following cardiac surgery	161
<b>Figure (22):</b>	Showing the final results for thrombolytic group	183

## ***List of Tables***

<b>Item</b>	<b>Page</b>
<b>Table (1):</b> Coated from: Recommendations for the management of patients after heart valve surgery.	35
<b>Table (2):</b> Maternal complication	43
<b>Table (3):</b> Fetal complication	43
<b>Table (4):</b> Anticoagulation from first week through 35 weeks of gestation	53
<b>Table (5):</b> Anticoagulation from week 36 to labor	53
<b>Table (6):</b> Proposed algorithm for prediction of thrombus in patients with mechanical prosthetic valve dysfunction	70
<b>Table (7):</b> Complications of thrombolytic therapy in prosthetic valves	88
<b>Table (8):</b> Contraindications to thrombolytic therapy	89
<b>Table (9):</b> Indications of thrombolytic therapy versus surgical treatment.	90
<b>Table (10):</b> Comparison between surgical and thrombolytic complications	91
<b>Table (11):</b> Showing the demographic characteristics	100
<b>Table (12):</b> Showing data about the prothetic valves	101
<b>Table (13):</b> Showing the coagulation profile on presentation	102
<b>Table (14):</b> Showing the drugs used for anticoagulation	103
<b>Table (15):</b> Showing coagulation profile history	103
<b>Table (16):</b> Showing compliance to anticoagulation drugs	104
<b>Table (17):</b> Showing the previous redo history	104
<b>Table (18):</b> Showing the diseases of hypercoagulability state	105
<b>Table (19):</b> Showing the diseases of hypercoagulability state	106
<b>Table (20):</b> Showing the past history of thrombosis	106
<b>Table (21):</b> Showing the duration of the symptoms	107
<b>Table (22):</b> showing the acute embolic events on presentation	108
<b>Table (23):</b> Showing the presenting rhythm	108

<b>Item</b>	<b>Page</b>
<b>Table (24):</b> Showing the rhythm changes till the end of ICU stay	109
<b>Table (25):</b> Showing the rhythm changes in the whole study	110
<b>Table (26):</b> Showing the difference in hemodynamics and instability between the two groups.	111
<b>Table (27):</b> Showing the hemodynamic results after treatment.	112
<b>Table (28):</b> Showing the difference in hemodynamics in the whole patients before and after treatment.	113
<b>Table (29):</b> Showing the differences in respiratory status between the two groups.	114
<b>Table (30):</b> Showing the respiratory improvement after thrombolytic therapy	115
<b>Table (31):</b> Showing the inotropic and respiratory support.	116
<b>Table (32):</b> Showing thrombi detection by TTE.	116
<b>Table (33):</b> Showing difference in LA size between the two groups.	117
<b>Table (34):</b> Showing difference in LV function between the two groups.	117
<b>Table (35):</b> Showing the difference between the two groups as regard the pressures and gradients before starting treatment.	117
<b>Table (36):</b> Showing the difference in TEE findings between the two groups.	119
<b>Table (37):</b> Showing the fluoroscopic assessment difference between the two groups.	120
<b>Table (38):</b> Showing the difference in infection incidence between the two groups.	120
<b>Table (39):</b> Showing the difference in renal functions between the two groups.	121
<b>Table (40):</b> Showing the pregnancy outcome in the two groups.	123
<b>Table (41):</b> Showing the mortality difference between the two groups.	123
<b>Table (42):</b> Showing the total ICU stay period in the two groups.	124

<b>Item</b>	<b>Page</b>
<b>Table (43):</b> Showing the improvement in pressures and gradients after thrombolytic therapy.	127
<b>Table (44):</b> Showing the improvement in leaflet motion in thrombolytic group assessed by fluoroscopy.	129
<b>Table (45):</b> Showing the bleeding complications in thrombolytic therapy group	130

# *Introduction*

Rheumatic heart disease remains a major problem in developing countries. Most often valve replacement is needed in case where the native valves are not suitable for either balloon interventional procedure or surgical repair (*Reddy et al., 1994*).

Despite the advances in the design, material, selection and manufacturing of prosthetic valves, the currently available models still are less than ideal and none of them approaches the normal human valves in either hemodynamic function or long term freedom from valve related complication (*Zeinen et al., 1990*).

Despite the improvement in the design of the anticoagulation, thrombosis is a well-recognized complication of prosthetic heart valves and is associated with substantial morbidity and mortality, actually mechanical valve obstruction is currently the main reason of mechanical valve re-operation (*Edmunds 1987*).

In recent series, valve thrombosis was the most common prosthesis related complication found at the autopsy, which is higher in mechanical valves 23% comparing the bioprosthetic valves 11% (*Zeinen et al., 1990*).

Prosthetic valve thrombosis is a life threatening complication with dramatic clinical presentation and rapid deterioration. The outcome is mostly fatal without intervention. However, the emergency operation with either valve replacement or thrombectomy with debridement was

considered the treatment of choice for acute prosthetic valve thrombosis, unfortunately, the operation in this situation associated with high mortality, which is ranging from 8 – 20 percent for urgent cases to 37.5%- 54.5% for emergency cases (*Husbye et al., 1983*).

### **Thrombolytic Therapy:**

Hence the pathogenesis of acute thrombosis in acute myocardial infarction and pulmonary embolism is the same of valve thrombosis, thrombolytic therapy was used as another modality in the treatment of stuck valves, which was initiated by Luluanga at 1971, when he used streptokinase in the treatment of tricuspid valve thrombosis (*Luluanga et al., 1971*).

Three years later Baille and his colleagues used thrombolytic therapy in the treatment of left sided stuck valves (*Baille et al., 1974*), since this time till now, thrombolytic therapy was used in management of stuck valves with different success rate (*Agaewal et al., 1997*).

Despite the agreement about thrombolytic safety in the treatment of prosthetic valve thrombosis, no special regimen is recommended and the percentage of re-thrombosis still undefined (*Yaron et al., 2000*).

Prosthetic valve thrombosis is the most common prosthetic related complication found at the autopsy, which is higher in mechanical valves (23%) comparing the bioprosthetic valves (11%) (*Zeinen et al., 1994*).

Prosthetic valve thrombosis is a life threatening complication with a dramatic clinical presentation and rapid deterioration, the outcome is mostly fatal without intervention (*Reddy et al., 1994*).

Inadequate level of anticoagulation is the most important factor involved in the pathogenesis of prosthetic valve thrombosis, adding to it many other factors including, the site and type of the prosthesis, the hypercoagulable state, the cardiac morphology and function (*Hering et al., 2001*).

Surgical treatment with either valve replacement or thrombectomy with debridement was considered the treatment of choice for acute prosthetic valve thrombosis, however, operation in this situation is technically demanding, with 37% to 55% mortality risk in emergency situation (*Deviri et al., 1991*).

Because the pathogenesis of acute thrombosis in acute myocardial infarction and pulmonary embolism is the same of valve thrombosis, thrombolytic therapy was tried as another modality in the treatment of stuck valves, which was initiated by Luluanga at 1971, when he used streptokinase in the treatment of tricuspid valve thrombosis (*Luluanga et al., 1971*).

Thrombolytic therapy has been accepted for routine treatment of tricuspid valve prosthetic occlusions, the concern for potential risk of systemic embolization has limited its use in left sided prosthetic valve thrombotic occlusion (*Roudaut et al, 1992*).

Thrombolytic therapy has been tried in acute left-sided prosthetic valve thrombosis as an alternative to emergency operation in case of critical clinical presentation, and when surgery is contraindicated (*Witchitz et al, 1980*). After that, thrombolytic therapy started to have an